Spero Therapeutics (SPRO) Stock Price, News & Analysis

Company Overview

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for serious bacterial infections. Headquartered in Cambridge, Massachusetts, the company aims to address the growing global threat of antibiotic resistance by creating therapies that target multidrug-resistant pathogens. Spero’s research platform leverages proprietary chemistry and deep biological insights to expand options in anti-infective care, with an emphasis on oral and intravenous formulations.

The company’s lead product candidate is tebipenem HBr (SPR994), an oral carbapenem antibiotic designed for the treatment of complicated urinary tract infections and pyelonephritis caused by multidrug-resistant Gram-negative bacteria. In parallel, Spero is advancing SPR206, an intravenous polymyxin derivative intended to treat serious hospital-acquired and ventilator-associated bacterial pneumonia. These candidates exemplify the company’s strategy to develop therapies that deliver strong antibacterial activity while minimizing toxicity and adverse effects.

Since its founding in 2014, Spero Therapeutics has built strategic partnerships to bolster its development and commercialization efforts, including collaborations with global pharmaceutical firms and research institutions. The company’s operations extend beyond the United States, encompassing clinical trial sites and regulatory interactions in North America, Europe, and Asia. By engaging with international health authorities and academic experts, Spero seeks to streamline the path to approval for critical new antibiotics.

Under the leadership of President and Chief Executive Officer Ankit Mahadevia, Spero has assembled a team of experienced biopharmaceutical professionals with expertise in infectious disease research, clinical development, and regulatory affairs. With a focus on scientific rigor and patient-centered innovation, the company continues to advance its pipeline toward regulatory milestones and potential commercialization, aiming to bring much-needed options to physicians and patients facing resistant infections.

Key Stats

• Today's Range: $2.89 to $3.00
• 50-Day Range: $0.58 to $3.02
• 52-Week Range: $0.51 to $3.09
• Volume: 474,996 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $166.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Spero Therapeutics Stock Analysis - MarketRank™

Spero Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 222nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Spero Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spero Therapeutics is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spero Therapeutics is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spero Therapeutics has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.05% of the float of Spero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spero Therapeutics does not currently pay a dividend.

Dividend Growth

Spero Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.80

Percentage of Shares Shorted

3.05% of the float of Spero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Spero Therapeutics is held by insiders.

Percentage Held by Institutions

Only 25.60% of the stock of Spero Therapeutics is held by institutions.

SPRO Stock Analysis - Frequently Asked Questions

How have SPRO shares performed this year?

Spero Therapeutics' stock was trading at $1.03 at the beginning of the year. Since then, SPRO shares have increased by 189.3% and is now trading at $2.98.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. The company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $11 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 123.50% and a negative net margin of 156.48%.

When did Spero Therapeutics IPO?

Spero Therapeutics (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Spero Therapeutics' major shareholders?

Top institutional shareholders of Spero Therapeutics include Capital Asset Advisory Services LLC (0.06%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRO
• CIK: 1701108
• Web: sperotherapeutics.com
• Phone: (857) 242-1600
• Fax: N/A
• Employees: 150
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +67.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.57 million
• Net Margins: -156.48%
• Pretax Margin: -156.48%
• Return on Equity: -123.50%
• Return on Assets: -58.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.56
• Quick Ratio: 2.56

Sales & Book Value

• Annual Sales: $47.98 million
• Price / Sales: 3.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 3.51

Miscellaneous

• Outstanding Shares: 55,910,000
• Free Float: 52,836,000
• Market Cap: $166.61 million
• Optionable: Optionable
• Beta: 1.33